Reena Pabari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Reena Pabari has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Camilla Cellarius
The Hospital for Sick Children Toronto Ontario Canada
2 shared publications- Christine Mauz-Körholz
Department of Paediatric Oncology, Justus-Liebig-University Giessen, Giessen, Germany
2 shared publications Clarisse Carcao
The Hospital for Sick Children Toronto Ontario Canada
2 shared publications- Dietrich Stoevesandt
Department of Radiology, University Hospital Halle, Halle/Saale, Germany
2 shared publications - Hollie Lai
Department of Radiology, Children’s Health Orange County, Orange, Calif
2 shared publications - Jamie E. Flerlage
Division of Pediatric Hematology/Oncology, Department of Pediatrics University of Rochester Medical Center Rochester New York USA
2 shared publications
Latest Publications
- 20 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (27) , 2590-2601
AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group
PURPOSE: The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562 ) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with newly diagnosed AML. We hypothesized that CPX-351 given during induction 1 and 2 would improve outcomes compared with DA. PATIENTS AND METHODS: Patients (21 years and younger) were randomly assigned to two cycles of DA induction (arm A = DA) or CPX-351 (arm B = CPX-351). All patients also received gemtuzumab ozogamicin in induction 1. Postinduction chemotherapy was according to risk assignment made at the end of induction 1 (EOI1). Those with high-risk (HR) AML received consolidation with allogeneic hematopoietic stem-cell transplantation (HSCT), whereas low-risk (LR) patients received chemotherapy alone. Protocol-specified interim analysis monitored efficacy and futility of CPX-351 induction with respect to the primary end point, event-free survival (EFS) from study entry. Disease-free survival (DFS) was calculated to determine the impact of EOI1 risk assignment. RESULTS: Seven hundred twenty-one eligible patients with FLT3 wild-type AML were randomly assigned to DA (n = 358) or CPX-351 (n = 363). Interim analysis determined that the futility monitoring rule was crossed because of inferior EFS in the CPX-351 arm and the random assignment was stopped. The two-year EFS from study entry was 62.2% for DA versus 51.2% for CPX-351 ( P = .011). DFS for patients with HR AML was comparable for both arms. However, DFS was significantly lower and cumulative incidence of relapse (CIR) was higher for LR patients assigned to CPX-351 versus DA (2-year DFS from EOI1: DA: 73.8% v CPX-351 57.5% [ P = .001]; 2-year CIR Arm DA: 23.6% v CPX-351: 39.9% [ P = .001]). CONCLUSION: CPX-351 was inferior to DA induction in the AAML1831 trial with differential EFS largely driven by events in LR patients.
- 20 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (27) , 2590-2601
AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group
PURPOSE: The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562 ) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with newly diagnosed AML. We hypothesized that CPX-351 given during induction 1 and 2 would improve outcomes compared with DA. PATIENTS AND METHODS: Patients (21 years and younger) were randomly assigned to two cycles of DA induction (arm A = DA) or CPX-351 (arm B = CPX-351). All patients also received gemtuzumab ozogamicin in induction 1. Postinduction chemotherapy was according to risk assignment made at the end of induction 1 (EOI1). Those with high-risk (HR) AML received consolidation with allogeneic hematopoietic stem-cell transplantation (HSCT), whereas low-risk (LR) patients received chemotherapy alone. Protocol-specified interim analysis monitored efficacy and futility of CPX-351 induction with respect to the primary end point, event-free survival (EFS) from study entry. Disease-free survival (DFS) was calculated to determine the impact of EOI1 risk assignment. RESULTS: Seven hundred twenty-one eligible patients with FLT3 wild-type AML were randomly assigned to DA (n = 358) or CPX-351 (n = 363). Interim analysis determined that the futility monitoring rule was crossed because of inferior EFS in the CPX-351 arm and the random assignment was stopped. The two-year EFS from study entry was 62.2% for DA versus 51.2% for CPX-351 ( P = .011). DFS for patients with HR AML was comparable for both arms. However, DFS was significantly lower and cumulative incidence of relapse (CIR) was higher for LR patients assigned to CPX-351 versus DA (2-year DFS from EOI1: DA: 73.8% v CPX-351 57.5% [ P = .001]; 2-year CIR Arm DA: 23.6% v CPX-351: 39.9% [ P = .001]). CONCLUSION: CPX-351 was inferior to DA induction in the AAML1831 trial with differential EFS largely driven by events in LR patients.
- Open Access
- 26 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2361-2364
Sirolimus is effective for paediatric Evans syndrome and secondary autoimmune cytopenias: A retrospective cohort study
- 26 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2361-2364
Open AccessSirolimus is effective for paediatric Evans syndrome and secondary autoimmune cytopenias: A retrospective cohort study
- 20 August 2026
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
When too much milk becomes dangerous: a retrospective review of the morbidity and mortality from very severe iron deficiency anaemia in otherwise healthy children
Introduction: Excessive cow's milk intake is a leading cause of iron deficiency (ID) and anaemia in toddlers. We sought to describe the complications of very severe ID anaemia (vsIDA) in children presenting to the largest tertiary paediatric hospital in Canada. Methods: This retrospective review included otherwise healthy children aged 0 to 5 years with haemoglobin (Hb) ≤ 50 g/L and ≥1 ID-specific marker (presenting 01/2020 to 12/2024). The primary objective was to analyze vsIDA-related complications; secondary objectives were to describe interventions received and identify risk factors for developing vsIDA (e.g., cow's milk intake, bottle use). Results: We identified 128 children with vsIDA, with a median age of 23 months and a median Hb of 38 g/L (12 to 50 g/L). Most children (84%) drank >500 mL/day of cow's milk; 91% of those ≥12 months old used a bottle. Excessive milk intake tended to be associated with lower Hb (P = 0.058); bottle use strongly correlated with excessive milk intake (P = 0.005). Of the 128 children, 57.8% were hospitalized, 47.7% received ≥1 red blood cell transfusion, and 21.1% received ≥1 iron infusion. Complications included developmental delay (28.1%), abnormal echocardiograms (11 of 13 performed, 85%), thrombotic events (n = 4; cerebral sinus venous thrombosis [CSVT] and/or deep vein thrombosis), and death (n = 2, one from cardiac failure and CSVT/stroke, the other from cardiac arrest). Conclusions: Significant morbidity and mortality can occur with vsIDA in otherwise healthy children, including developmental delay, heart failure, strokes, and death. These complications can be avoided with improved education, screening, dietary counselling, and removing bottles from children >12 to 18 months old.
- 20 August 2026
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
When too much milk becomes dangerous: a retrospective review of the morbidity and mortality from very severe iron deficiency anaemia in otherwise healthy children
Introduction: Excessive cow's milk intake is a leading cause of iron deficiency (ID) and anaemia in toddlers. We sought to describe the complications of very severe ID anaemia (vsIDA) in children presenting to the largest tertiary paediatric hospital in Canada. Methods: This retrospective review included otherwise healthy children aged 0 to 5 years with haemoglobin (Hb) ≤ 50 g/L and ≥1 ID-specific marker (presenting 01/2020 to 12/2024). The primary objective was to analyze vsIDA-related complications; secondary objectives were to describe interventions received and identify risk factors for developing vsIDA (e.g., cow's milk intake, bottle use). Results: We identified 128 children with vsIDA, with a median age of 23 months and a median Hb of 38 g/L (12 to 50 g/L). Most children (84%) drank >500 mL/day of cow's milk; 91% of those ≥12 months old used a bottle. Excessive milk intake tended to be associated with lower Hb (P = 0.058); bottle use strongly correlated with excessive milk intake (P = 0.005). Of the 128 children, 57.8% were hospitalized, 47.7% received ≥1 red blood cell transfusion, and 21.1% received ≥1 iron infusion. Complications included developmental delay (28.1%), abnormal echocardiograms (11 of 13 performed, 85%), thrombotic events (n = 4; cerebral sinus venous thrombosis [CSVT] and/or deep vein thrombosis), and death (n = 2, one from cardiac failure and CSVT/stroke, the other from cardiac arrest). Conclusions: Significant morbidity and mortality can occur with vsIDA in otherwise healthy children, including developmental delay, heart failure, strokes, and death. These complications can be avoided with improved education, screening, dietary counselling, and removing bottles from children >12 to 18 months old.
- Open Access
- 11 May 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (9) , 2281-2283
GLUT1 Deficiency Syndrome with Coexistent Movement Disorder and Anemia
- 11 May 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (9) , 2281-2283
Open AccessGLUT1 Deficiency Syndrome with Coexistent Movement Disorder and Anemia
- 30 January 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Imaging pitfalls in pediatric, adolescent, and young adult Hodgkin lymphoma: a SEARCH for CAYAHL initiative to bridge multidisciplinary patient care
Pediatric Hodgkin lymphoma (pHL) is a highly curable malignancy in children, adolescents, and young adults, and current treatment strategies aim to minimize adverse late effects. Many patients are enrolled in clinical trials with centralized review for both initial and interim staging. Although academic guidelines provide a structured framework for image interpretation, real-world clinical scenarios sometimes present imaging pitfalls that require nuanced judgment. Morphological and metabolic imaging pitfalls refer to misinterpretation of findings that occur during staging, disease evaluation, or post-treatment surveillance. In pHL, such pitfalls may result from suboptimal imaging conditions, concurrent inflammatory, infectious, or other findings. These findings do not indicate neoplastic disease but rather are manifestations of other processes specific to each tissue or organ. This Staging, Evaluation, and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) initiative represents a transatlantic collaboration among multidisciplinary professionals, aiming to disseminate the insights gained from decades of centralized review experience in North American and European clinical trials. This article aims to optimize patient care by integrating imaging and clinical expertise in disease staging and surveillance. Although not intended as a comprehensive staging guide, it highlights recurrent imaging pitfalls that may lead to incorrect staging or response assessment. By encouraging interdisciplinary exchange, this work seeks to complement existing literature and serve as a troubleshooting guide for situations where clinical realities diverge from academic paradigms.
- 30 January 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Imaging pitfalls in pediatric, adolescent, and young adult Hodgkin lymphoma: a SEARCH for CAYAHL initiative to bridge multidisciplinary patient care
Pediatric Hodgkin lymphoma (pHL) is a highly curable malignancy in children, adolescents, and young adults, and current treatment strategies aim to minimize adverse late effects. Many patients are enrolled in clinical trials with centralized review for both initial and interim staging. Although academic guidelines provide a structured framework for image interpretation, real-world clinical scenarios sometimes present imaging pitfalls that require nuanced judgment. Morphological and metabolic imaging pitfalls refer to misinterpretation of findings that occur during staging, disease evaluation, or post-treatment surveillance. In pHL, such pitfalls may result from suboptimal imaging conditions, concurrent inflammatory, infectious, or other findings. These findings do not indicate neoplastic disease but rather are manifestations of other processes specific to each tissue or organ. This Staging, Evaluation, and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) initiative represents a transatlantic collaboration among multidisciplinary professionals, aiming to disseminate the insights gained from decades of centralized review experience in North American and European clinical trials. This article aims to optimize patient care by integrating imaging and clinical expertise in disease staging and surveillance. Although not intended as a comprehensive staging guide, it highlights recurrent imaging pitfalls that may lead to incorrect staging or response assessment. By encouraging interdisciplinary exchange, this work seeks to complement existing literature and serve as a troubleshooting guide for situations where clinical realities diverge from academic paradigms.
- 21 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31626
Prolonged Hypogammaglobulinemia in a Child With Down Syndrome After Treatment of Acute Lymphoblastic Leukemia With Immunochemotherapy Including Blinatumomab
- 21 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31626
Prolonged Hypogammaglobulinemia in a Child With Down Syndrome After Treatment of Acute Lymphoblastic Leukemia With Immunochemotherapy Including Blinatumomab
- Open Access
- 13 September 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (18) , 4856-4865
Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL
Hodgkin lymphoma (HL) involving the central nervous system (CNS) is exceedingly rare. Information regarding the presentation, management, treatment, and outcome of patients with CNS HL is limited to case reports or small series. We describe 45 pediatric patients with 55 extra-axial CNS lesions at diagnosis with HL from a cohort of 4995 patients enrolled on Children’s Oncology Group AHOD1331 and the European Network for Pediatric Hodgkin lymphoma C1 and C2 trials, with an overall incidence of 0.9%. Up to 82.2% of patients had a single CNS lesion in the thoracic, lumbar, or sacral spine. In the evaluated cohort, HL did not occur within the CNS parenchyma. Lesions extended into the extra-axial CNS space from adjacent soft tissue or bone and never directly infiltrated through the dura into the brain or spinal cord. Patients with CNS involvement had a twofold greater incidence of extranodal lesions than previously reported cohorts without CNS involvement. After 2 cycles of chemotherapy, 89.1% of CNS lesions demonstrated a complete metabolic response and >75% decrease in volume. Thirteen CNS lesions (23.6%) received irradiation; none were sites of disease relapse. Relapse occurred at the site of 2 lesions involving the CNS, both of which had an adequate interim response to chemotherapy. In summary, we present, to our knowledge, the largest reported cohort of systemic HL involving the CNS at diagnosis, demonstrating that these lesions originate from surrounding tissues, extend into the extra-axial CNS space, and respond similarly to other nodal and extranodal disease. The trials were registered at www.clinicaltrials.gov as #NCT02166463, #NCT00433459, and #NCT02684708.
- 13 September 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (18) , 4856-4865
Open AccessHodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL
Hodgkin lymphoma (HL) involving the central nervous system (CNS) is exceedingly rare. Information regarding the presentation, management, treatment, and outcome of patients with CNS HL is limited to case reports or small series. We describe 45 pediatric patients with 55 extra-axial CNS lesions at diagnosis with HL from a cohort of 4995 patients enrolled on Children’s Oncology Group AHOD1331 and the European Network for Pediatric Hodgkin lymphoma C1 and C2 trials, with an overall incidence of 0.9%. Up to 82.2% of patients had a single CNS lesion in the thoracic, lumbar, or sacral spine. In the evaluated cohort, HL did not occur within the CNS parenchyma. Lesions extended into the extra-axial CNS space from adjacent soft tissue or bone and never directly infiltrated through the dura into the brain or spinal cord. Patients with CNS involvement had a twofold greater incidence of extranodal lesions than previously reported cohorts without CNS involvement. After 2 cycles of chemotherapy, 89.1% of CNS lesions demonstrated a complete metabolic response and >75% decrease in volume. Thirteen CNS lesions (23.6%) received irradiation; none were sites of disease relapse. Relapse occurred at the site of 2 lesions involving the CNS, both of which had an adequate interim response to chemotherapy. In summary, we present, to our knowledge, the largest reported cohort of systemic HL involving the CNS at diagnosis, demonstrating that these lesions originate from surrounding tissues, extend into the extra-axial CNS space, and respond similarly to other nodal and extranodal disease. The trials were registered at www.clinicaltrials.gov as #NCT02166463, #NCT00433459, and #NCT02684708.
- Open Access
- 4 August 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (8) , 5579-5584
Training for Wellness in Pediatric Oncology: A Focus on Education and Hidden Curricula
Pediatric oncologists have the privilege of caring for children and families facing serious, often life-threatening, illnesses. Providing this care is emotionally demanding and associated with significant risks of stress and burnout for oncologists. Traditional approaches to physician burnout and wellbeing have not emphasized the potential roles of education and training in mitigating this stress. In this commentary, we discuss the contribution that education, particularly in the areas of palliative and psychosocial oncology, can make in preparing oncologists for the work that they do. We argue that by adequately providing oncologists with the skills they need for their work, we can reduce their risk of burning out. We also discuss the importance of paying attention to hidden and formal curricula to ensure that messages provided in formal education programs are supported by informal training experiences.
- 4 August 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (8) , 5579-5584
Open AccessTraining for Wellness in Pediatric Oncology: A Focus on Education and Hidden Curricula
Pediatric oncologists have the privilege of caring for children and families facing serious, often life-threatening, illnesses. Providing this care is emotionally demanding and associated with significant risks of stress and burnout for oncologists. Traditional approaches to physician burnout and wellbeing have not emphasized the potential roles of education and training in mitigating this stress. In this commentary, we discuss the contribution that education, particularly in the areas of palliative and psychosocial oncology, can make in preparing oncologists for the work that they do. We argue that by adequately providing oncologists with the skills they need for their work, we can reduce their risk of burning out. We also discuss the importance of paying attention to hidden and formal curricula to ensure that messages provided in formal education programs are supported by informal training experiences.
- 3 June 2022
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (3) , e401-e405
The Clinical Landscape of NRAS-mutated Juvenile Myelomonocytic Leukemia-like Myeloproliferation Includes Children With Costello Syndrome
Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive pediatric disorder characterized by pathologic myeloproliferation because of alterations in RAS pathway genes. NRAS-mutated JMML encompasses a broad range of clinical severity. Herein we describe 4 unique cases of NRAS-mutated JMML and JMML-like myeloproliferation, 2 with somatic mutations and 2 with germline mutations. These cases illustrate the diverse clinical and hematologic presentation of this subtype of JMML, including a very unusual example presenting with Auer rods. Lastly, this is the first report of patients with phenotypic Costello syndrome presenting with JMML-like myeloproliferation, highlighting an important clinical phenomenon that has not been previously described.
- 3 June 2022
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (3) , e401-e405
The Clinical Landscape of NRAS-mutated Juvenile Myelomonocytic Leukemia-like Myeloproliferation Includes Children With Costello Syndrome
Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive pediatric disorder characterized by pathologic myeloproliferation because of alterations in RAS pathway genes. NRAS-mutated JMML encompasses a broad range of clinical severity. Herein we describe 4 unique cases of NRAS-mutated JMML and JMML-like myeloproliferation, 2 with somatic mutations and 2 with germline mutations. These cases illustrate the diverse clinical and hematologic presentation of this subtype of JMML, including a very unusual example presenting with Auer rods. Lastly, this is the first report of patients with phenotypic Costello syndrome presenting with JMML-like myeloproliferation, highlighting an important clinical phenomenon that has not been previously described.
- 13 August 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (12) , e29296
Hodgkin lymphoma involving the sternum
- 13 August 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (12) , e29296
Hodgkin lymphoma involving the sternum